2,603 Shares in CVS Health Co. (NYSE:CVS) Purchased by NBW Capital LLC

NBW Capital LLC bought a new position in CVS Health Co. (NYSE:CVS) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 2,603 shares of the pharmacy operator’s stock, valued at approximately $206,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Bryn Mawr Capital Management LLC grew its holdings in CVS Health by 74.0% during the 3rd quarter. Bryn Mawr Capital Management LLC now owns 43,213 shares of the pharmacy operator’s stock worth $3,017,000 after acquiring an additional 18,385 shares during the period. Value Partners Investments Inc. boosted its holdings in CVS Health by 26.5% during the third quarter. Value Partners Investments Inc. now owns 991,601 shares of the pharmacy operator’s stock worth $69,261,000 after buying an additional 207,702 shares during the last quarter. Sonora Investment Management Group LLC grew its position in shares of CVS Health by 1.6% during the 3rd quarter. Sonora Investment Management Group LLC now owns 50,488 shares of the pharmacy operator’s stock worth $3,525,000 after buying an additional 774 shares during the period. Checchi Capital Advisers LLC raised its position in shares of CVS Health by 2.3% in the 3rd quarter. Checchi Capital Advisers LLC now owns 10,405 shares of the pharmacy operator’s stock valued at $726,000 after acquiring an additional 233 shares during the period. Finally, Personal CFO Solutions LLC boosted its stake in CVS Health by 2.6% during the 3rd quarter. Personal CFO Solutions LLC now owns 19,355 shares of the pharmacy operator’s stock worth $1,351,000 after acquiring an additional 491 shares during the last quarter. 80.66% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, EVP Prem S. Shah sold 29,473 shares of CVS Health stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $76.95, for a total transaction of $2,267,947.35. Following the sale, the executive vice president now directly owns 39,765 shares of the company’s stock, valued at approximately $3,059,916.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.24% of the company’s stock.

CVS Health Stock Performance

NYSE:CVS opened at $69.39 on Friday. The company has a debt-to-equity ratio of 0.77, a quick ratio of 0.63 and a current ratio of 0.86. CVS Health Co. has a fifty-two week low of $64.41 and a fifty-two week high of $83.25. The company has a market cap of $87.46 billion, a price-to-earnings ratio of 10.74, a PEG ratio of 0.91 and a beta of 0.52. The stock has a fifty day moving average price of $75.42 and a 200-day moving average price of $73.70.

CVS Health (NYSE:CVS) last released its earnings results on Wednesday, February 7th. The pharmacy operator reported $2.12 EPS for the quarter, beating the consensus estimate of $2.01 by $0.11. CVS Health had a net margin of 2.33% and a return on equity of 15.25%. The firm had revenue of $93.81 billion for the quarter, compared to analyst estimates of $90.58 billion. During the same period last year, the firm earned $1.99 EPS. The business’s quarterly revenue was up 11.9% compared to the same quarter last year. As a group, equities analysts anticipate that CVS Health Co. will post 8.32 EPS for the current fiscal year.

CVS Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Investors of record on Monday, April 22nd will be paid a $0.665 dividend. This represents a $2.66 annualized dividend and a yield of 3.83%. The ex-dividend date is Friday, April 19th. CVS Health’s dividend payout ratio (DPR) is presently 41.18%.

Analyst Ratings Changes

Several equities research analysts have weighed in on the stock. Leerink Partnrs reiterated an “outperform” rating on shares of CVS Health in a report on Monday, February 26th. Piper Sandler raised their price target on CVS Health from $93.00 to $94.00 and gave the stock an “overweight” rating in a research report on Friday, March 15th. Cantor Fitzgerald reissued an “overweight” rating and set a $87.00 target price on shares of CVS Health in a research note on Wednesday, April 10th. Royal Bank of Canada lowered their price objective on shares of CVS Health from $86.00 to $84.00 and set an “outperform” rating for the company in a research report on Thursday, February 8th. Finally, SVB Leerink began coverage on shares of CVS Health in a research note on Monday, February 26th. They issued an “outperform” rating and a $88.00 target price for the company. Four research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to MarketBeat, CVS Health currently has a consensus rating of “Moderate Buy” and an average price target of $89.44.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.